Published in Pharmaceuticals (Basel) on August 20, 2013
Peptide aptamers: development and applications. Curr Top Med Chem (2015) 0.80
Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. Nucleic Acids Res (2015) 0.80
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers (Basel) (2015) 0.79
The natural chemopreventive agent sulforaphane inhibits STAT5 activity. PLoS One (2014) 0.78
The Chemopreventive Phytochemical Moringin Isolated from Moringa oleifera Seeds Inhibits JAK/STAT Signaling. PLoS One (2016) 0.75
How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5. PLoS One (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 15.33
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature (1998) 5.04
Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J (1994) 4.03
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Tracking STAT nuclear traffic. Nat Rev Immunol (2006) 2.99
Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A (1995) 2.79
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev (2008) 2.68
ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem (1999) 2.41
The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res (2007) 2.27
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood (2009) 1.89
Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol (2008) 1.85
Importin alpha nuclear localization signal binding sites for STAT1, STAT2, and influenza A virus nucleoprotein. J Biol Chem (2003) 1.81
Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood (2007) 1.81
Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene (2005) 1.76
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev (2007) 1.45
Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene (2003) 1.40
Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A (2000) 1.38
Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res (2008) 1.29
Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med (2013) 1.27
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology (2007) 1.19
Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene (2006) 1.16
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
SnapShot: JAK-STAT signaling. Cell (2007) 1.10
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol (2011) 1.05
Peptide aptamers as guides for small-molecule drug discovery. Drug Discov Today (2006) 1.05
Unphosphorylated STAT and heterochromatin protect genome stability. FASEB J (2010) 1.05
Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene (2007) 1.00
Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2011) 0.99
Nongenomic STAT5-dependent effects on Golgi apparatus and endoplasmic reticulum structure and function. Am J Physiol Cell Physiol (2011) 0.98
Mitochondrial translocation of signal transducer and activator of transcription 5 (STAT5) in leukemic T cells and cytokine-stimulated cells. Biochem Biophys Res Commun (2010) 0.98
Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures. Nat Protoc (2006) 0.97
STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem (2009) 0.95
STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol (2006) 0.95
Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol Cancer Res (2008) 0.92
Peptide aptamer libraries. Comb Chem High Throughput Screen (2008) 0.91
Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol (2009) 0.90
Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol (2011) 0.90
Yeast two-hybrid methods and their applications in drug discovery. Trends Pharmacol Sci (2011) 0.88
Stat5 as a diagnostic marker for leukemia. Expert Rev Mol Diagn (2008) 0.88
Transcription factor regulation in mammary epithelial cells. Domest Anim Endocrinol (2002) 0.87
Peptide aptamers for small molecule drug discovery. Methods Mol Biol (2009) 0.86
Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Mol Med (2012) 0.86
Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered (2012) 0.85
The eleven-year switch of peptide aptamers. J Biol (2008) 0.84
The versatile regulation of cellular events by Jak-Stat signaling: from transcriptional control to microtubule dynamics and energy metabolism. Horm Mol Biol Clin Investig (2012) 0.82
STAT5 contributes to antiapoptosis in melanoma. Melanoma Res (2008) 0.79
A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. JAKSTAT (2012) 0.79
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet (2010) 4.06
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
STAT1 acts as a tumor promoter for leukemia development. Cancer Cell (2006) 2.00
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood (2002) 1.96
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79
Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res (2009) 1.78
A mutation in the ATP2 gene abrogates the age asymmetry between mother and daughter cells of the yeast Saccharomyces cerevisiae. Genetics (2002) 1.75
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology (2011) 1.60
Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest (2007) 1.51
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood (2006) 1.50
Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia (2007) 1.49
Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev (2007) 1.45
The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol (2008) 1.42
The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem (2003) 1.42
Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res (2002) 1.38
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol (2002) 1.37
Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood (2008) 1.31
Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev (2004) 1.30
Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells (2010) 1.23
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood (2008) 1.20
STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp Hematol (2007) 1.19
STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood (2009) 1.17
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther (2010) 1.11
The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res (2004) 1.11
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer (2004) 1.10
A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells (2013) 1.09
The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia (2006) 1.09
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol (2009) 1.06
Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci (2005) 1.06
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat (2003) 1.05
Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem (2003) 1.05
Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol (2010) 1.05
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood (2010) 1.04
STAT3 silencing inhibits glioma single cell infiltration and tumor growth. Neuro Oncol (2013) 1.02
Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology (2010) 1.00
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2. Mol Endocrinol (2006) 0.97
Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology (2012) 0.97
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) (2009) 0.96
The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood (2002) 0.95
A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: insights from gene expression profiling. Cytokine (2006) 0.94
Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Mol Cell Endocrinol (2012) 0.93
Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol Cancer Res (2008) 0.92
The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res (2004) 0.92
Peptide aptamer libraries. Comb Chem High Throughput Screen (2008) 0.91
Promising new sources for pluripotent stem cells. Stem Cell Rev (2010) 0.91
STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem (2011) 0.90
The potential of amniotic fluid stem cells for cellular therapy and tissue engineering. Expert Opin Biol Ther (2011) 0.90
A detailed protocol for bacterial artificial chromosome recombineering to study essential genes in stem cells. Methods Mol Biol (2008) 0.90
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res (2008) 0.90
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol (2014) 0.89
Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells. Curr Drug Targets Immune Endocr Metabol Disord (2005) 0.89
Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle (2012) 0.89
Comparative proteomic analysis of proliferating and functionally differentiated mammary epithelial cells. Mol Cell Proteomics (2003) 0.88
Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol (2007) 0.88
Stat5 assumes distinct functions in mammary gland development and mammary tumor formation. Front Biosci (Landmark Ed) (2012) 0.88
The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death. Mol Cancer Res (2010) 0.88
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther (2012) 0.88
The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors (2005) 0.87
Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood (2003) 0.87
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Mol Med (2012) 0.86
Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J Virol (2012) 0.86
Comparison of the nuclear proteomes of mammary epithelial cells at different stages of functional differentiation. Proteomics (2007) 0.86
Expression of a carboxy terminally truncated Stat5 with no transactivation domain in the mammary glands of transgenic mice inhibits cell proliferation during pregnancy, delays onset of milk secretion, and induces apoptosis upon involution. Mol Reprod Dev (2006) 0.85
From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. Hum Gene Ther Clin Dev (2013) 0.84
Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Arch Biochem Biophys (2013) 0.84
Establishment of a mouse xenograft model for mycosis fungoides. Exp Dermatol (2004) 0.84
Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Front Biosci (Landmark Ed) (2011) 0.84
Sensitized phenotypic screening identifies gene dosage sensitive region on chromosome 11 that predisposes to disease in mice. EMBO Mol Med (2011) 0.84
Projection angle dependence in grating-based X-ray dark-field imaging of ordered structures. Opt Express (2013) 0.83